Nonablative hematopoietic cell transplantation for the treatment of metastatic renal cell carcinoma

Research output: Contribution to journalReview article

2 Scopus citations


Nonablative hematopoietic cell transplantation (HCT) is becoming a preferred treatment for those recipients in whom the potential toxicity risk of standard ablative allogeneic therapy may be unacceptable. Graft-versus-malignancy effects may be generated against epithelial malignancies which are similar to the graft-versus-leukemia activity that is well documented in human hematological malignancies. Renal cell carcinoma has been shown to be responsive to immunotherapy with recombinant human cytokines and may be an ideal model for exploring this novel therapy. Clinical investigations have demonstrated regression of metastatic renal cell carcinoma occurs in some patients following nonablative allogeneic HCT. However, graft-versus-host disease remains a significant toxicity of nonablative transplantation, and further investigations are warranted to further evaluate this promising approach and to improve its safety.

Original languageEnglish (US)
Pages (from-to)805-812
Number of pages8
JournalBone marrow transplantation
Issue number12
StatePublished - Dec 1 2002


  • Hematopoietic cell transplantation
  • Nonmyeloablative
  • Renal cell carcinoma

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Fingerprint Dive into the research topics of 'Nonablative hematopoietic cell transplantation for the treatment of metastatic renal cell carcinoma'. Together they form a unique fingerprint.

  • Cite this